Last updated 2026-08-23
- Acquired Biostór Ireland
- Raised $778k IPO, Aug 2026
- Raised $643k IPO, Mar 2026
Total raised
$9.5M
Last: PIPE 2026-08
Stage
Public
Founded
2020
Headcount
12
HQ
Haifa, Israel
Sector
Biotechnology
About
NurExone Biologic Inc. is a biopharmaceutical company focused on developing regenerative exosome-based therapies for traumatic central nervous system injuries. Their lead candidate, ExoPTEN, is being developed for acute spinal cord injury and optic nerve damage, utilizing exosomes as nanocarriers to deliver drugs for neuron rewiring and regeneration. The company holds an exclusive worldwide license for its breakthrough technology, which originated from research at the Technion and Tel Aviv University.
Funding history · 11 rounds · $9.5M total
11 events/rounds · $9.5M Total Funding: $6.0M in Private Equity, $3.4M in Public Equity
Aug 2026
Jun 2026
Mar 2026
Nov 2025
★ James Richardson
Aug 2025
★ Jay Richardson★ James Richardson
Aug 2025
Sep 2024
★ other participants★ James A. Richardson
Mar 2024
Mar 2024
Jan 2024
Aug 2023
Acquisitions · 1
Date unknown
Biostór Ireland
Undisclosed
Headcount over time
12 employees (2026-09) · 1 point
Offices
Haifa, Israel · HQ / main office
Q&A
- What is NurExone's primary focus?
- NurExone Biologic Inc. is a biopharmaceutical company focused on developing regenerative exosome-based therapies for traumatic central nervous system injuries, including spinal cord and optic nerve damage.
- What was NurExone's most recent funding round?
- NurExone's most recent funding round was a PIPE round in August 2026, raising $1,066,078.
- Has NurExone received any grants recently?
- In October 2023, NurExone received a Grant of $1,000,000 from Israel Innovation Authority (IIA).
- When did NurExone complete its Seed funding round?
- NurExone completed a Seed funding round in March 2024, raising $1,020,000.
- When did NurExone secure Debt Financing?
- NurExone secured Debt Financing in August 2025, with participation from Jay Richardson.
- When did NurExone conduct an IPO?
- NurExone conducted an IPO in March 2026, raising $880,751.
- Who is the current CEO of NurExone?
- Lior Shaltiel is the Chief Executive Officer and Board Director of NurExone, appointed in 2022.
Team · 29
Yoram Drucker
Founder · Co-Founder, VP Strategic Development & Chairman
Prof. Shulamit Levenberg
Founder · Scientific Advisory Board
Lior Shaltiel
Chief Executive Officer & Board Director
Eran Ovadya
Chief Financial Officer
Tali Kizhner
R&D Director
Ina Sarel
Head of CMC, Quality and Regulation
Ram Petter
Head of Operations
Kineret Taler
Head of Preclinical Studies
Shy Rubin
Tech Transfer Engineer
Nirit Drori-Carmi
Head of Bioprocess Development
Sharon Baumgarten-Soueid
QA Manager
Igor Paz
BioProcess Science & Technology Expert
Alina Freiman Khaikin
In-Process Control Manager
Rina Wasserman
Head of Analytical Development
Sandra Rushrush
Senior R&D Researcher
Mira Assad
R&D Scientist
Tal Rubin Ofek
executives
Hilla Hazan
Finance Manager
Limor Chen
Head of Scientific Collaboration and External Partnerships
Oded Orgil
Director
Eyal Gabbai
Director
David Stolick
Board Member
Gadi Riesenfeld
Scientific Advisory Board
Prof. Nahshon Knoller
Scientific Advisory Board
Prof. Gabriel Zeilig
Scientific Advisory Board
Prof. Michael Belkin
Scientific Advisory Board
Prof. Teodoro Forcht Dagi
Scientific Advisory Board
Gabriel Eldor
Professional Advisor
Nisim Perets
Professional Advisor
Sectors & technology
Primary sector
Biotechnology
Technologies
Business model
B2BB2C
Highlights
Patents
Tags
biopharmaceuticalexosome-therapyregenerative-medicinespinal-cord-injuryneurological-disordersbiotech
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nurexone.com/ |
|---|---|
| linkedin.com/company/nurexone-biologic/ | |
| X / Twitter | x.com/NBiologic |
Identifiers & details
| Legal name | NurExone Biologic Inc. |
|---|---|
| Founded | 2020 |
| Employees (exact) | 12 |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| Biostór Ireland |
Radar intelligence
Patents
| EPO | 3 |
|---|
Web history (Wayback)
| Domain | nurexone.com |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516209202 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2020-06-17 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 1 — charge (1) |
| Registered address | פארק תעשיה גוטווירט הטכניון ב חיפה |
Recent registry events
| Date | Event |
|---|---|
| 2026-04-12 | סילוק שעבוד |